Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes

AIMS/HYPOTHESIS: The aim of this study was to determine if retention of C-peptide following immunotherapy using recombinant GAD65 conjugated to aluminium hydroxide (GAD-alum) is influenced by HLA risk haplotypes DR3-DQ2 and DR4-DQ8. METHODS: HLA-dependent treatment effect of GAD-alum therapy on C-pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hannelius, Ulf, Beam, Craig A., Ludvigsson, Johnny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476912/
https://www.ncbi.nlm.nih.gov/pubmed/32754804
http://dx.doi.org/10.1007/s00125-020-05227-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476912/
https://www.ncbi.nlm.nih.gov/pubmed/32754804
http://dx.doi.org/10.1007/s00125-020-05227-z

Ejemplares similares